AMRX Stock Overview
A global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Amneal Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.79 |
| 52 Week High | US$9.48 |
| 52 Week Low | US$5.18 |
| Beta | 1.05 |
| 1 Month Change | 10.43% |
| 3 Month Change | 12.26% |
| 1 Year Change | 63.08% |
| 3 Year Change | 111.81% |
| 5 Year Change | 175.55% |
| Change since IPO | -41.44% |
Recent News & Updates
Recent updates
There's No Escaping Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Muted Revenues
Feb 17
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Nov 10Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success
Jul 10Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Apr 15Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?
Mar 19Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry
Dec 28Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company
Dec 10Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Nov 28Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt
Sep 24Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Aug 08Amneal Pharmaceuticals Could Have An Upbeat Q2
Jul 10These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively
Apr 18Amneal Pharmaceuticals: Risk Still Persists
Jan 23Amneal Pharma reaffirms 2022 guidance
Jan 10Amneal joins hands with Orion to commercialize generic products in Europe and more countries
Jan 04Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load
Dec 20Amneal Pharmaceuticals large shareholder TPG cuts stake
Dec 14FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203
Nov 11Amneal Pharmaceuticals Q3 2022 Earnings Preview
Nov 03Shareholder Returns
| AMRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.3% | -5.9% | -4.1% |
| 1Y | 63.1% | -0.8% | 6.6% |
Return vs Industry: AMRX exceeded the US Pharmaceuticals industry which returned -0.5% over the past year.
Return vs Market: AMRX exceeded the US Market which returned 7.5% over the past year.
Price Volatility
| AMRX volatility | |
|---|---|
| AMRX Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.4% |
Stable Share Price: AMRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AMRX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 8,300 | Chirag Patel | www.amneal.com |
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals.
Amneal Pharmaceuticals, Inc. Fundamentals Summary
| AMRX fundamental statistics | |
|---|---|
| Market cap | US$2.72b |
| Earnings (TTM) | -US$116.89m |
| Revenue (TTM) | US$2.79b |
1.0x
P/S Ratio-23.3x
P/E RatioIs AMRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMRX income statement (TTM) | |
|---|---|
| Revenue | US$2.79b |
| Cost of Revenue | US$1.78b |
| Gross Profit | US$1.02b |
| Other Expenses | US$1.13b |
| Earnings | -US$116.89m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 36.35% |
| Net Profit Margin | -4.18% |
| Debt/Equity Ratio | -5,581.8% |
How did AMRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/13 03:31 |
| End of Day Share Price | 2025/03/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amneal Pharmaceuticals, Inc. is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |